Modern approaches to minimally invasive ablative treatment of solid tumors involve the use of miniature instruments and combined treatments. These can be enhanced with ultrasound imaging that depicts tumor margins; facilitates guidance, delivery, and dosage of local chemotherapy; and can monitor the effectiveness of the treatment. This paper describes the advantages of ultrasound guided cryosurgery combined with local chemotherapy delivered in multilamellar, echogenic microcapsules of 5-FU ("µcaps") using a xenograft tumor model.
Introduction
Cryosurgery has become an alternative Minimally Invasive Surgical (MIS) modality for the treatment of prostate cancer (2). The use of multiple thin cryoprobes has allowed shaping the ice balls to the prostate lesion and ultrasonographic guidance has yielded better results in terms of local eradication. Although a destructive end temperature threshold, i.e., -40º C, and the repetition of the freeze-thaw (F/T) cycle have been considered as standard procedure for complete eradication of malignant tumors (25), some studies have shown that prostate tissue requires end freeze temperatures below -40º C for complete thermal ablation (3). This uncertainty has led to a slow adoption of cryosurgery by the clinical community when it comes to the primary therapy for the treatment of prostate disease (4). Among the alternative chemotherapeutic options for prostate cancer (5), liposome delivery of chemotherapy drugs (15, 17) has only been partially successful. Cryosurgery has been associated with systemic chemotherapy to increase its local efficacy, however, results have been inconsistent (6, 7, 13) . A recent in vitro (1) experiment used a combination of free drug, 5-fluorouracil, 5-FU, given prior to freezing of a human prostate cancer cell line, PC3, which resulted in an increased kill efficacy. Interestingly, the drug and cryosurgical regimen were used at levels individually ineffective. In 2002, Mir and Rubinski (11) reported similar results in vitro with the concomitant use of a single freeze-thaw cycle and free bleomycine on B16 F0 melanoma cells. A quantitative, non-invasive measurement of cancer cell survival is critical to in vivo studies of the effectiveness of cryosurgery or chemotherapy of solid tumors. Techniques of fluorescence imaging (9, 10) , are now widely available for such in vivo evaluations. Recently, using a luciferase assay, Caceres et al. (12) were able to image and quantify in vivo the action of systemic chemotherapy against the subcutaneous transplant of a human prostate tumor, DU145, in rodents. These results and the development of novel echogenic, microcapsules containing chemo-therapeutic drugs led us to investigate the feasibility of combining cryosurgery and interstitial microencapsulated chemotherapy for the treatment of human prostate cancer. Bioluminescent tumors were subjected to a partial cryosurgical ablation and/or interstitial chemotherapy with a novel microcapsule delivery system encapsulating both 5-fluorouracil (5-FU) and a widely used contrast oil (Ethiodol ® , Savage Labs). The main objectives were to use in vivo imaging, i.e., ultrasound (US) and bioluminescence imaging (BLI), to characterize the acute effects on tumor cell growth of small injections of microencapsulated drug (5-FU), a single freeze-thaw cryosurgical procedure, and the combination of both methods. The 5-FU microcapsules were deposited in the hypothermic region of the tumor just outside the ice ball margin. The results of this preliminary study show superior tumor inhibition from the combined treatment.
Material and Methods
Tumors DU-145 Luc+ is a human prostate carcinoma cell line (HTB-81; ATCC) that has been transformed with the firefly luciferase-expressing vector as previously described (8). Athymic nu/nu male mice, 8-10 weeks old, are injected in the subcutaneous (s/c) region of the right hind limb. The tumors are treated on day 20 and 21 after implantation. The mice are subdivided in two series: for Series I (n=9) 5 mice are injected with µcaps alone and 4 served as controls, and for Series II (n=9) 5 mice received a combination of cryosurgery and µcaps, and 4 received cryosurgery alone (Table I) . Tumor dimensions are taken before and at various times after the treatments with a caliper. These experiments have been conducted according to the IACUC at Rumbaugh-Goodwin Institute For Cancer Research (RGI).
Microcapsules
Microcapsules (µcaps) made by NASA (JSC, Houston, TX) cotaining 2%w/v 5-FU (Sigma) and 20% w/v of echogenic contrast oil, Ethiodol (Savage Labs). Their average diameter was 8.08 microns. The total dose of 5-FU was either 7.2ng/20 µl or 10.81 ng/30 µl. Treated tumors received two interstitial injections for a total of 25.6 ng/gm tumor in the chemotherapy group. Blue, hydrophobic microspheres were mixed with the 5-FU µcaps or suspended alone in PBS, and then injected as sham controls. The blue microspheres aided the histological examination of the tumor tissues and facilitated re-location of the 5-FU µcaps injection sites.
Luciferase Imaging
The animals are injected intra-peritoneally (i.p.) with 2.0 mg D-luciferin (Molecular Probes,) in 0.1ml sterile water, anaesthesized with xylazine (3mg/mL) and ketamine (7mg/mL) in PBS, and then placed in the Molecular Light Imager, NightOwl (LB 981 Berthold Technologies,). BL images are captured using a two-step process and the Night Owl "WinLight" dedicated software according to a previously published procedure (12). Animals are sacrificed at Day 7, The Ice Ball (IB) Kill ratio is the ratio of necrosis area to IB area at the end of the freeze application.
tumors are excised, weighed, measured for size, then imaged for bioluminescence quantitation (BLQ) whole, then sliced into multiple thick layers. After the imaging the slices were frozen at ∼ 1º C/min to -15º C for subsequent cryosectioning and histological examination.
Ultrasound Imaging
Immediately after BLI, the anesthetized animal is checked with a portable black and white ultrasound commercial device (Hawk 2102 & Merlin 1101, BK Medical Systems, FL USA) and a 12MHz linear array transducer (8570). Animals were imaged before and immediately after operation, then at day 2, 4, and 7 in Series I, at day 3, and 7 in Series II.
Interstitial Microencapsulated Chemotherapy
Series I was injected with a 25 gauge hypodermic needle (Becton Dickinson, NJ) at day of operation in two opposite sites of the tumor, i.e., in the caudal and cephalic sites, with 20 or 30 microliters of microcapsules containing 0.363 ng/µl of 5-FU and 20% v/v Ethiodol.
Series II was injected with a suspension of microcapsules (65,200 per ul PBS) containing 5-FU and Ethiodol. Each treated tumor received a total of 40 or 60 microliters of suspended µcaps containing a total dose of 14.4 or 21.6ng, respectively, of 5-FU. A small quantity of the blue microspheres was also mixed with the 5-FU µcaps to facilitate location of the injection sites during cytopathology evaluations.
Cryosurgery and Cryochemotherapy
Cryoablation: Under anesthesia, a 3 mm diameter cryoprobe (Critical Care Innovation, VA, USA) is inserted vertically into tumor through a skin puncture. A 0.5 mm bead wire insulated (PFA Teflon ® ) type T thermocouple (Omega, CT, USA) is placed per-cutaneously into tumor a few mm off the probe wall. The probe tip end contains a thermocouple located at 5mm from tip end. Both thermocouples are connected to a data-logging module (SuperLogics, CP 8218) and to a laptop (HP Pavilion ze 4145) running a proprietary thermal monitoring and simulation software (CryoDiff.V211, Sodelog, Grenoble, France). During the cryosurgical procedure, this software measures probe temperatures and uses them to predict: i) the tumor temperature (+/-2º C), (assuming cylindrical symmetry, by solving the equation of thermal diffusivity), and ii) IB formation and temperatures of tumor and adjacent tissues at various distances beyond the IB. Cryoablation consisted of freezing a portion of the tumor from skin surface to the deep margin and leaving a volume of peripheral tumor unfrozen. The probe tip was purposely not centered in the tumor, so that the ice ball never overlaped the entire tumor area. A single freeze-thaw (F/T) cycle was used without hold time. Within 5 minutes, the IB thawed spontaneously at room temperature. The puncture was sealed with cyanoacrylate adhesive (VetBond™, 3M, MN USA).
Cryochemotherapy: For the combined therapy (see Fig. 3), the procedure was similar except that at the end of the freezing cycle, and at the ice ball margin, two deposits of 5-FU µcaps in 20 or 30 µl were injected in opposite sites of the tumor, i.e., caudal and cephalic.
Results
Our experimental approach was designed to model the clinical situation of palliative or incomplete cryosurgery where the majority, but not all, of the tumor is ablated by a single treatment. Four treatment groups were compared: non-treated controls, partial cryoablation alone, microencapsulated 5-FU interstitial chemotherapy, and combined cryochemotherapy. Figure 1 illustrates the relative locations of the depots of 5-FU microcapsules and iceball formation within each group of treated tumors. Suboptimal doses of 5-FU microcapsules were used purposely to elucidate any drug sensitization effects rendered by the hypothermia in the tumor margins.
Morphology and Macroscopic Evaluations
Although the s.c. DU-145 luc prostate tumors were minimally invasive tumors and had well defined capsule margins, there was no obvious difference between the size of the untreated controls and those tumors treated with 5-FU µcaps alone. High resolution Frequency US imaging and real-time measurements provided better information on tumor growth and location of the echogenic 5-FU microcapsules, but US was not as useful for discerning tumor cell inhibition as was the bioluminescence imaging (BLI). The inhibitory effects of the 5-FU µcaps were clearly demonstrated using Bioluminescence quantification (BLQ).
Bioluminescence and In Vivo Tumor Growth
Periodic BLI within 30 minutes after injection of luciferin substrate was quite definitive for measuring the inhibition of viable tumor growth in treated tumors. The BLQ was a good in vivo monitor of surviving tumor cells that showed subtle significant differences in the tumor inhibition effectiveness of all treatments. BLI also provided useful information combined with the US measurements of tumor margins and size measurements: evidencing a rapid growth of the control tumors and clear differences in the degree of inhibition rendered by either treatment or the combination therapy. Figure The spatial maps of photon intensity isocurves (bottom panels) also illustrate the reduction in viable tumor cells near the two injection sites (cranial & caudal).
Ultrasound Visualization of Echogenic µcaps
The black and white screen allows a clear display of the needle and echogenic µcaps as they flowed out of the needle. US can visualize very small quantities (2 µl) of echogenic µcaps.
In most but not all cases, it was possible to see the echogenic µcaps in the same locations for several days after injection. However, the µcaps were no longer detectable after day 4.
Control studies indicate that approximately 18% of the µcaps had been lyzed open by Day 4 due to body temperature effects alone (data not shown). Thus, with very small volumes it was not surprising that the µcaps could not be detected by US after Day 4. It was easy to confirm the location of the µcap deposits in the tumors by microscopic examination of 5-10 µm histological tissue sections. We also used blue microspheres, about (5 µm) as co-markers for the 5-FU µcaps.
Microcapsule Size, Distribution and Loading
The aqueous drug compartment included a fluorescent molecule (Lumiphos™-FITC) that allowed fluorescence microscopy measurements of the size distribution and drug loading of the µcaps. The mean drug content was 10.81 ng of 5-FU per 2×10 6 µcaps injected into each depot site for a total dose of 25.6 or 38.7 ng/g of tumor. These multilamellar µcaps release the 5-FU by both diffusion and progressive lysis at body temperature. Analysis of the control µcaps confirmed that 17% of the total drug had been released from microcapsule lysis by Day 4 after injection and approximately 25% was released due to capsule degradation by Day 7 (data not shown). Additional 5-FU was released by diffusion through the microcapsule walls.
Cryosurgery and Thermal Data
Freeze time average is 114 +/-40.7 seconds. The IB kill ratio, i.e., the ratio of the necrotic area and the IB area at the end of the freeze period, i.e., end IB, at Day 3 and Day 7 was similar in the treated (64%) and control group (65%), see Table I . Software calculated freezing temperatures of -12.9 +/-3.9 ºC at the IB margin which corresponded to necrotic margins observed on day 3 after cryosurgery: The calculated temperature at the outer tumor margin was + 8.6 +/-4.9 ºC and the cooling rate at IB margin was -14.3 +/-6.2 ºC/min. 
Bioluminescence Quantitative Analysis of Therapeutic Effects
In vivo BL quantification (BLQ) allowed inter and intragroup comparisons.
Non-Treated: BLQ measurements of non-treated tumors showed increased mean luminescence from viable tumor cells that reached 4.6x greater by Day 4 and more than 7.6x greater by Day 7 compared to Day 0.
Chemoablation Effects: Tumors treated with 5-FU µcaps showed dramatic reduction in viable cell luminescence at Day 2 and Day 4. The mean of viable tumor cells in control tumors by day 2 was significantly more than those treated with 5-FU µcaps and 5.6 times greater at day 4 than the treated tumors. (p=0.036); by day 7, the mean viable tumor cells were 2.7 times greater in the controls compared to the treated group (Figure 4) . The magnitude of the inhibitory effect of the microcapsules at day 4 was surprising, considering the fact that the 5-FU doses were considered as barely threshold for 5-FU inhibition of rapidly growing tumors.
Cryoablation: BLQ of the tumors treated with partial cryoablation alone shows that by day 3, the mean of viable tumor cells was 20 times greater in controls than in treated tumors, and 1.87 times greater at Day 7.
Combined Cryoablation and 5-FU Treatment: BLQ of the combination treatment showed that the mean viable tumor cells in controls were 34 times greater at Day 3 than those treated by cryoablation followed by µcaps chemotherapy, and more than 350 times greater at Day 7 than the treated tumors (see Figure 5 ). Figure 6 shows the time course comparison for all treatment groups of tumors using BLQ. It is apparent that both the 5-FU µcaps and partial cryoablation individually have significant inhibitory effect on the growth of the tumor cells through Day 3 or 4; however, thereafter the surviving tumor cells outgrow the suppression. The combined modality of cryo, followed by 5-FU µcaps, gave an increased and longer lasting inhibitory effect on tumor growth than the individual treatments.
Discussion
Our studies demonstrated that ultrasound and bioluminescencebased measurements can be used to evaluate the kinetics of tumor inhibition, using luciferase activity measured in xenogenic human prostate tumors treated with a new type of microencapsulated chemotherapy, partial cryosurgery, or a combination of both methods. Our xenograft mouse model and BLQ proved to be valuable tools for measuring the relative efficacy of all three treatments in just a 7-day period. In vivo bioluminescence imaging (BLI) was used to detect the scant numbers of photons that emanate from luciferase-tagged cells. It allowed for an easy and fast planar imaging of the target (19, 20) and could detect significant differences between treatments.
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Advantages of Echogenic Microcapsules
NASA originally developed the unique multilamellar microcapsules, used herein, specifically for intra-arterial delivery of multiple chemotherapeutic drugs for chemoembolization of solid vascular tumors (31) (32) (33) (34) . For the present studies, the 5-FU µcaps were optimized further for imaging by clinical ultrasound devices. We were able to guide the needle and detect the deposition of µcaps in the warm tumor as well as in the hypothermic zone peripheral to the ice ball, using a commercial 12 MHz US system. In previous experiments (unpublished data), we injected 20-30 µl of free Ethiodol and showed that US could only image the contrast bolus during and only for a few hours after injection, since it was immediately dispersed into the least resistant portions of the nearby tissues. However, our echogenic µcaps, containing only 2-3 µl of Ethiodol (10x less), were imaged during release from the needle and were easily re-located for days following interstitial injection into s.c. tumors or normal deep tissues.
Effects of 5-FU Chemotherapy
Minimal doses (25 ng/g tumor) of microencapsulated 5-FU dramatically inhibited tumor growth starting within two days, with maximum inhibition by the 4 th day, after injection [p<0.05]. Diffusion release of the 5-FU would not account for the early onset of tumor cell inhibition, however, these µcaps begin to degrade shortly after exposure to body temperatures; consequently, approximately 17% of the drug would have been released by microcapsule lysis by Day 4 after injection. This fact is supported by the disappearance of the echogenic microcapsule deposit after Day 4 as measured by US imaging.
Cryochemotherapy
In tumors treated with the cryochemotherapy combination, the viable cell inhibition was much more effective than with either treatment alone. The combined therapy reduced the tumor cell growth by more than 95% compared to the growth of the non-treated controls for the entire 7-day period. The cryo-or 5-FU µcaps treatments individually were less effective and lasted only three or four days. It would appear that this combined therapy is potentially synergistic, but longer studies are needed to determine optimum doses for the most lasting effects. The enhancement of the combined regimen is not totally unexpected. There is a growing body of evidence that dramatic local changes in tumor temperature (< 30 ºC) will affect the cytotoxicity of antitumor drugs. Earlier studies on cryochemotherapy of B16/BDF1 melanoma tumors indicated an increased tumor uptake of peplomycin, but not adriamycin, and increased vascular permeability within the tumor (6). Recent studies have shown that cryosurgery increases bleomycin penetration into B16F0 melanoma cells (11) . In vitro studies on PC3 prostate cells using 5-FU administered 2-4 days prior to cryoablation, showed a 30% increased loss of cell viability (p<0.001) at freezing temperatures of -5 to -20 ºC (1). Hyperthermia also enhances liposomal chemotherapy (18, 36, 37) .
The advantages of cryochemotherapy have been pursued for some time (13) and are gaining renewed interest because of the known limitations of "aggressive" cryosurgery (21), and the well-known risks of an over-freeze in the prostate area. Liposomal chemotherapy (15) also is used for various lesions or for prostate cancer (16). Our results show that the enhanced cytotoxic effect of moderate tissue cooling rate and slightly positive end temperature during a single freeze/thaw period is quite sufficient to enhance the tumor inhibitory effects of 5-FU, even at sub-threshold doses and when delivered by injection of microcapsules. However the ice ball kill ratio 64% is steady from Day 3 to Day 7, similar in both groups, and compatible with the existing literature (26, 27) . Our thermal data are also compatible with publications (23) showing that lethal temperatures in vivo are closer to -15 ºC than to -40 ºC and that slow freezing rates, as well as a single freeze application, are lethal to tumor cells (22). Since our injections of microencapsulated 5-FU were at ice ball margin, which were verified with US, the tumor cells in this region were cooled at low rates, i.e., less than 50 ºC/min (22), and therefore did not experience any intracellular freezing. Our results support the hypothesis that slow cooling rates just to temperatures above zero, in the vicinity of +10 ºC, combined with local microcapsule chemotherapy may be sufficient to create a synergistic toxic effect on tumor cells. The importance of chemotherapy enhancement in the hypothermic regions external to the iceball emphasizes the advantages of real-time monitoring and prediction of the thermal history of the tumor. Moreover, hypothermia may have selective beneficial effects on normal cells, a fact that might be of high clinical usefulness. In a recent paper (24), Matijasevic shows that wild-type fibroblast cells survive much higher doses of 5-FU than p53-deficient cells when subjected to mild hypothermia, i.e., 28 ºC. According to the author, the loss of p-53 expression would correspond to an inability to arrest the cell cycle at low temperature and to an increased sensitivity to prolonged hypothermia.
A major advantage of the focal, microcapsule chemotherapy is the elimination of the usual side effects of systemic I.V. administration. The combined advantages of temperature induced microvessel permeability, increased tumor cell permeability, and the longer drug residence times afforded by microcapsules indicate that our results are not unexpected.
Since co-encapsulation of multiple drug combinations, and custom design of microcapsule characteristics are now possible, the potential for new therapy regimens is extensive, not only with cryogenic cooling, but also with RF, micro-wave, mechanical or ionizing treatments. Our findings point to the potential development of minimally invasive, echo-guided, and controlled, cryochemo procedures. The use of multipledose regimens and sustained drug release from focal microcapsule injections should be combined with thermally controlled cryosurgery. Such cryochemotherapy procedures should induce local hypothermia sufficient to enhance cytotoxic drug efficacy in prostate and other solid tumors.
Conclusions
We have demonstrated that in vivo BL imaging of genetically engineered tumor cells and US imaging of the tumor combined with local deposition of echogenic microcapsules can be used in xenograft tumor models quite effectively to evaluate the efficacy of novel cryochemotherapy regimens.
A new understanding and approach was developed for combining improved cryosurgery methods and local injections of microencapsulated chemotherapy drugs. The advantages of real-time ultrasound imaging include improved placement of the cryosurgery probe and real-time confirmation of the local tissue distribution of the echogenic microcapsules during and after injection. The combined methodologies provide a shorter and safer surgical procedure, increased tumor inhibition, and allow for post surgical ultrasound monitoring of the resulting tumor regression as well as prompt determination for microcapsule chemotherapy re-dosing.
Our results demonstrated, for the first time, that the single moderate freeze of a human prostate tumor combined with bifocal microcapsule chemotherapy (5-FU) has a better and longer inhibitory effect on tumor growth compared to the tumor growth inhibition rendered by cryosurgery or local microcapsule chemotherapy alone. These experiments also demonstrate that the microcapsules can be excellent echogenic markers of the injection sites and that their lifetime in the tumor tissue can be monitored with conventional US imaging.
The enhanced efficacy of the combined cryochemotherapy treatments in our tumor model, designed to mimic the situation where tumor loci cannot be reached or completely eliminated by cryoablation, give encouragement for further studies to determine how long this effect will last. Such new therapeutic modalities could be used for palliative and curative treatments of solid tumors.
